Multiple sclerosis (MS) is the most common idiopathic inflammatory disease of the central
nervous system. The distinction between MS and other benign or fulminant inflammatory …

The natural history of multiple sclerosis is highly variable. There is substantial heterogeneity
in the clinical manifestations but at this point it is reasonable to consider all idiopathic …

OBJECTIVE: To evaluate the efficiency of mitoxantrone in multiple sclerosis. METHODS:
Forty two patients with confirmed multiple sclerosis, selected as having a very active disease …

New therapies are being evaluated by clinical trials and, if efficacious, introduced for the
treatment of adult MS. The role of these new and existing agents in the management of …

Multiple sclerosis (MS) is thought to be an autoimmune disease mediated by T lymphocytes
that recognize myelin components of the central nervous system. In a 1-year double-blind …

We designed a randomized, placebo-controlled, multicentre trial involving 51 relapsing-
remitting multiple sclerosis patients to determine the clinical efficacy of mitoxantrone …

Multiple sclerosis is a common disease of the central nervous system affecting
approximately 1 million young adults, mostly women, worldwide. 1 It is characterized by …

We conducted a meta-analysis of randomized controlled clinical trials on steroid treatment
for multiple sclerosis and optic neuritis. Of the 25 trials comparing steroids and controls …

Multiple sclerosis is a chronic autoimmune disease of the central nervous system that results
in varying degrees of disability. Progressive multiple sclerosis, characterized by a steady …

Multiple sclerosis is postulated to be a Th1-type cell-mediated autoimmune disease. We
investigated cytokine profiles in patients with progressive multiple sclerosis by using …